Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Seattle Genetics (SGEN) and Clearside Biomedical (CLSD).
Seattle Genetics (SGEN)
Needham analyst Chad Messer maintained a Buy rating on Seattle Genetics today and set a price target of $121.00. The company’s shares closed last Monday at $100.81, close to its 52-week high of $101.40.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 5.0% and a 39.8% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Ionis Pharmaceuticals Inc.
Currently, the analyst consensus on Seattle Genetics is a Moderate Buy with an average price target of $86.80, representing a -10.1% downside. In a report released today, Piper Jaffray also reiterated a Buy rating on the stock with a $95.00 price target.
See today’s analyst top recommended stocks >>
Clearside Biomedical (CLSD)
Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical today. The company’s shares closed last Monday at $0.83, close to its 52-week low of $0.56.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -3.2% and a 39.2% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Clearside Biomedical with a $2.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
